10x Genomics, Inc. (TXG) Revenue, Earnings & Financial Statements
$56.30NASDAQ: TXGMarket Cap $6.84B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
10x Genomics, Inc. most recently reported annual revenue of $643.0M, a net loss of $44.0M. Revenue grew at an average annual rate of 16.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
10x Genomics, Inc.: Revenue rose from $71.0M in 2017 to $643.0M in 2025, a change of +805.6% over 8 years; net profit was positive in 0 of 9 reported years; operating margin moved from -25.9% to -17.3%, a shift of +8.6 percentage points; the most recent year shows a net loss of $44.0M.
Income Statement — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$71.0M
$146.0M
$246.0M
$299.0M
$490.0M
$516.0M
$619.0M
$611.0M
$643.0M
Operating Expenses
$89.0M
$257.0M
$275.0M
$384.0M
$543.0M
$684.0M
$884.0M
$805.0M
$754.0M
Operating Profit
−$18.0M
−$111.0M
−$29.0M
−$85.0M
−$53.0M
−$168.0M
−$265.0M
−$195.0M
−$111.0M
Operating Margin
-25.9%
-75.7%
-11.8%
-28.6%
-10.8%
-32.5%
-42.9%
-31.9%
-17.3%
Other Income
$0
−$2.0M
−$2.0M
−$449.0M
−$1.0M
$6.0M
$17.0M
$17.0M
$71.0M
Interest
$1.0M
$2.0M
$3.0M
$2.0M
$1.0M
$0
$0
$0
$0
Depreciation
$4.0M
$4.0M
$7.0M
$19.0M
$28.0M
$33.0M
$44.0M
$44.0M
$44.0M
Profit Before Tax
−$19.0M
−$112.0M
−$31.0M
−$534.0M
−$54.0M
−$162.0M
−$249.0M
−$178.0M
−$40.0M
Tax rate (%)
-0.1%
-0.1%
-0.7%
-1.5%
-8.4%
-2.5%
-2.5%
-2.8%
-9.1%
Net Profit
−$19.0M
−$112.0M
−$31.0M
−$543.0M
−$58.0M
−$166.0M
−$255.0M
−$183.0M
−$44.0M
EPS
−$1.62
−$8.40
−$0.80
−$5.37
−$0.53
−$1.46
−$2.18
−$1.52
−$0.35
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$184.0M
$141.0M
$153.0M
$152.0M
$165.0M
$155.0M
$173.0M
$149.0M
$166.0M
$151.0M
$151.0M
$151.0M
Operating Expenses
$239.0M
$203.0M
$195.0M
$193.0M
$215.0M
$194.0M
$143.0M
$181.0M
$186.0M
$168.0M
$171.0M
$167.0M
Operating Profit
−$55.0M
−$61.0M
−$42.0M
−$41.0M
−$50.0M
−$39.0M
$30.0M
−$32.0M
−$20.0M
−$17.0M
−$20.0M
−$16.0M
Operating Margin
-30.0%
-43.6%
-27.3%
-27.4%
-30.2%
-25.4%
17.4%
-21.6%
-11.8%
-11.3%
-12.9%
-10.7%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$47.0M
−$58.0M
−$37.0M
−$34.0M
−$48.0M
−$34.0M
$37.0M
−$28.0M
−$15.0M
−$13.0M
−$19.0M
−$18.0M
Tax rate (%)
-5.0%
-3.7%
-2.2%
-3.8%
-1.3%
-2.5%
6.7%
2.6%
-7.0%
-4.8%
3.8%
-5.1%
Net Profit
−$49.0M
−$60.0M
−$38.0M
−$36.0M
−$49.0M
−$34.0M
$35.0M
−$27.0M
−$16.0M
−$13.0M
−$18.0M
−$19.0M
EPS
−$0.41
−$0.50
−$0.32
−$0.30
−$0.40
−$0.28
$0.28
−$0.22
−$0.13
−$0.10
−$0.14
−$0.15
Over the 9 years reported for 10x Genomics, Inc., borrowings increased from $11.0M in 2017 to $158.0M in 2025, cash stood at $474.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.47 times.
Balance Sheet — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$76.0M
$124.0M
$606.0M
$929.0M
$1.0B
$1.0B
$965.0M
$919.0M
$1.0B
Current Assets
$68.0M
$106.0M
$481.0M
$774.0M
$748.0M
$635.0M
$596.0M
$584.0M
$684.0M
Cash
$48.0M
$65.0M
$424.0M
$664.0M
$587.0M
$220.0M
$359.0M
$344.0M
$474.0M
Inventory
$5.0M
$9.0M
$15.0M
$30.0M
$60.0M
$82.0M
$74.0M
$83.0M
$56.0M
Receivables
$13.0M
$28.0M
$33.0M
$51.0M
$85.0M
$104.0M
$115.0M
$88.0M
$82.0M
Fixed Assets
$7.0M
$11.0M
$49.0M
$120.0M
$230.0M
$359.0M
$345.0M
$310.0M
$287.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$5.0M
$0
$0
$8.0M
$210.0M
$29.0M
$49.0M
$49.0M
Other Assets
$0
$0
$0
$0
$5.0M
$5.0M
$5.0M
$5.0M
$5.0M
Total Liabilities
$188.0M
$344.0M
$186.0M
$190.0M
$201.0M
$223.0M
$224.0M
$209.0M
$245.0M
Current Liabilities
$22.0M
$32.0M
$63.0M
$118.0M
$110.0M
$131.0M
$127.0M
$118.0M
$153.0M
Borrowings
$11.0M
$30.0M
$30.0M
$63.0M
$82.0M
$95.0M
$95.0M
$83.0M
$158.0M
Other Liabilities
$178.0M
$315.0M
$156.0M
$127.0M
$119.0M
$128.0M
$129.0M
$126.0M
$87.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
−$113.0M
−$220.0M
$420.0M
$739.0M
$818.0M
$806.0M
$741.0M
$710.0M
$796.0M
For 10x Genomics, Inc., operating cash flow was positive in 3 of 9 reported years; free cash flow in the latest year was $130.0M; free cash flow was positive in 1 of 9 years.
Cash Flow Statement — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$11.0M
−$76.0M
$35.0M
−$218.0M
−$21.0M
−$34.0M
−$15.0M
$7.0M
$136.0M
Investing Cash Flow
−$8.0M
−$14.0M
−$86.0M
−$77.0M
−$208.0M
−$483.0M
$84.0M
−$45.0M
−$19.0M
Financing Cash Flow
$1.0M
$2.0M
$4.0M
$24.0M
$0
$0
$0
$0
$0
Net Cash Flow
$6.0M
$22.0M
$406.0M
$212.0M
−$93.0M
−$369.0M
$132.0M
−$15.0M
$130.0M
Free Cash Flow
−$14.0M
−$83.0M
−$8.0M
−$256.0M
−$123.0M
−$165.0M
−$65.0M
−$6.0M
$130.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.26
EV / EBITDA
156.98
FCF Yield
1.26%
Quick Ratio
4.66
Interest Coverage
—
Return 1Y
258.60%
Return 3Y
33.51%
Return 5Y
-62.40%
10x Genomics, Inc. (TXG) financials — frequently asked questions
What is 10x Genomics, Inc.'s annual revenue?
10x Genomics, Inc. (TXG) reported annual revenue of $643.0M in its most recent fiscal year.
What is 10x Genomics, Inc.'s net profit?
10x Genomics, Inc. (TXG) reported a net loss of $44.0M in its most recent fiscal year.
What is TXG EV/EBITDA?
10x Genomics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 156.98.
Revenue and earnings of other Biotechnology stocks